01.002 RWE KR Apr 2022 D 27-04-2022

Rheumatology real-world evidence studies are clinically important, but require careful interpretation

  • Real-world evidence studies such as a recent study by Fisher (1) examining the persistence of JAK1/3 inhibitor tofacitinib in patients with RA compared to the persistence of bDMARD of a large, retrospective new user cohort from in a research database, are informative but require cautious interpretation because findings are dependent on a variety of medical and nonmedical influences
  • Real-world data are clinically important, and drug survival with appropriate caveats is a good surrogate for continued efficacy and lack of AE necessitating discontinuation
  • Confirmation from similar studies in large registries from a variety of countries with differing medical systems would help to clarify the picture and advise on drug persistence of any novel therapy
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at